drugset / Trial / NCT01254565

Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

NCT01254565

Phase 2 Completed 87 enrolled KAI Pharmaceuticals
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to characterize the safety and tolerability and efficacy of multiple ascending doses of etelcalcetide in hemodialysis patients for the treatment of secondary hyperparathyroidism (HPT).

Timeline

Start
2011-02-20
Primary completion
2011-07
Completion
2011-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Etelcalcetide Other / unclassified 5 mg Intravenous
Subject Etelcalcetide Other / unclassified 10 mg Intravenous
Subject Etelcalcetide Other / unclassified 20 mg Intravenous